BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 24727243)

  • 1. Novel metronidazole-chalcone conjugates with potential to counter drug resistance in Trichomonas vaginalis.
    Anthwal A; Rajesh UC; Rawat MS; Kushwaha B; Maikhuri JP; Sharma VL; Gupta G; Rawat DS
    Eur J Med Chem; 2014 May; 79():89-94. PubMed ID: 24727243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of nitazoxanide against some metronidazole-resistant and susceptible Trichomonas vaginalis isolates.
    Abdel-Magied AA; Hammouda MM; Mosbah A; El-Henawy AA
    J Infect Chemother; 2017 Apr; 23(4):230-233. PubMed ID: 28131737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Trichomonas vaginalis activity of ursolic acid derivative: a promising alternative.
    Bitencourt FG; de Brum Vieira P; Meirelles LC; Rigo GV; da Silva EF; Gnoatto SCB; Tasca T
    Parasitol Res; 2018 May; 117(5):1573-1580. PubMed ID: 29572567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of metronidazole-resistant Trichomonas vaginalis with tinidazole: case reports of three patients.
    Hager WD
    Sex Transm Dis; 2004 Jun; 31(6):343-5. PubMed ID: 15167642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations.
    Seña AC; Bachmann LH; Hobbs MM
    Expert Rev Anti Infect Ther; 2014 Jun; 12(6):673-85. PubMed ID: 24555561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of two plant extracts against vaginal trichomoniasis.
    El-Sherbini GT; El Gozamy BR; Abdel-Hady NM; Morsy TA
    J Egypt Soc Parasitol; 2009 Apr; 39(1):47-58. PubMed ID: 19530609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis.
    Cudmore SL; Delgaty KL; Hayward-McClelland SF; Petrin DP; Garber GE
    Clin Microbiol Rev; 2004 Oct; 17(4):783-93, table of contents. PubMed ID: 15489348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New chemotherapeutic nitroheterocycles active against 5-nitroimidazole-resistant strains of trichomonads.
    Meingassner JG; Nesvadba H; Mieth H
    Arzneimittelforschung; 1981; 31(1):6-8. PubMed ID: 6971111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro cytotoxic effects of ornidazole, metronidazole and ciprofloxacin against Trichomonas vaginalis trophozoites.
    Inceboz T; Inceboz U; Ozturk S
    J Chemother; 2004 Oct; 16(5):459-62. PubMed ID: 15565912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole-resistant and -susceptible strains of Trichomonas vaginalis.
    Blaha C; Duchêne M; Aspöck H; Walochnik J
    J Antimicrob Chemother; 2006 Feb; 57(2):273-8. PubMed ID: 16344287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of metronidazole-resistant Trichomonas vaginalis--a new approach.
    Mammen-Tobin A; Wilson JD
    Int J STD AIDS; 2005 Jul; 16(7):488-90. PubMed ID: 16004628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis.
    Dunne RL; Dunn LA; Upcroft P; O'Donoghue PJ; Upcroft JA
    Cell Res; 2003 Aug; 13(4):239-49. PubMed ID: 12974614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis.
    Adagu IS; Nolder D; Warhurst DC; Rossignol JF
    J Antimicrob Chemother; 2002 Jan; 49(1):103-11. PubMed ID: 11751773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of metronidazole-resistant Trichomonas vaginalis.
    Goldman LM; Upcroft JA; Workowski K; Rapkin A
    Sex Health; 2009 Dec; 6(4):345-7. PubMed ID: 19917205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of netropsin dihydrochloride against the viability, cytopathogenicity and hemolytic activity of Trichomonas vaginalis clinical isolates.
    Abou Gamra MM; Kamel HH; Ezz Eldin HM; Taha Zahran FM
    J Infect Chemother; 2019 Dec; 25(12):955-964. PubMed ID: 31189504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetarsol pessaries in the treatment of metronidazole resistant Trichomonas vaginalis.
    Chen MY; Smith NA; Fox EF; Bingham JS; Barlow D
    Int J STD AIDS; 1999 Apr; 10(4):277-80. PubMed ID: 12035784
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-Trichomonas vaginalis activity of 1,10-phenanthroline-5,6-dione-based metallodrugs and synergistic effect with metronidazole.
    Vargas Rigo G; Petro-Silveira B; Devereux M; McCann M; Souza Dos Santos AL; Tasca T
    Parasitology; 2019 Aug; 146(9):1179-1183. PubMed ID: 30207253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenical pessaries in the treatment of metronidazole-resistant Trichomonas vaginalis.
    Walker PP; Hall RE; Wilson JD
    Int J STD AIDS; 1997 Jul; 8(7):473. PubMed ID: 9228600
    [No Abstract]   [Full Text] [Related]  

  • 19. Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population.
    Krashin JW; Koumans EH; Bradshaw-Sydnor AC; Braxton JR; Evan Secor W; Sawyer MK; Markowitz LE
    Sex Transm Dis; 2010 Jul; 37(7):440-4. PubMed ID: 20351623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of genotypes in relation to metronidazole susceptibility patterns in Trichomonas vaginalis isolated from South African pregnant women.
    Mabaso N; Abbai N
    Parasitol Res; 2021 Jun; 120(6):2233-2241. PubMed ID: 34002261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.